检索结果-南通市图书馆

Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-a

引用

World Journal of Gastroenterology 2005年第34期11卷 5401-5403页

作者： Kazutaka Kurokohchi Kouichi Takaguchi Keiji Kita Tsutomu Masaki Shigeki Kuriyama Third Department of Internal Medicine Kagawa University School of Medicine 1750-1 Ikenobe Miki-cho Kita-gun Kagawa 761-0793 Japan Department of Internal Medicine Kagawa Prefectural Central Hospital 5-4-16 Ban-cho Takamatsu Kagawa 760-8557 Japan

We report a case of hepatocellular carcinoma （HCC） treated successfully by transarterial chemoembolization （TACE） followed by combination therapy of 5-fluorouracil （5-FU） and pegylated interferon-α （PEG-IFN-α）. In the present case, the patient had massive and advanced HCC with a diameter of over 8 cm located in segment 7 （S7） of the liver. Furthermore, the tumor invaded into the major branch of the portal vein （Vp3）. After TACE, combined administration of 5-FU and PEG-IFN-α was performed for 5 too. HCC was totally eradicated and the serum levels of tumor markers were markedly decreased by the treatment. Although it has been reported that the combined use of conventional IFN-α and 5-FU showed striking effects on HCC in some cases, this case may suggest the more promising effect of PEG-IFN-α with a long-lasting effect, in the combined use with 5-FU for the treatment of massive advanced HCC.

关键词： Hepatocellular carcinoma 5-Fluorouracil pegylated interferon-α Combination therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The combination of PD-1 blockade with interferon-αhas a synergistic effect on hepatocellular carcinoma

引用

Cellular & Molecular Immunology 2022年第6期19卷 726-737页

作者： Ying Zhu Mo Chen Da Xu Tian-En Li Ze Zhang Jian-Hua Li Xiang-Yu Wang Xin Yang Lu Lu Hu-Liang Jia Qiong-Zhu Dong Lun-Xiu Qin Department of General Surgery Huashan HospitalCancer Metastasis InstituteFudan University12 Urumqi Road(M)Shanghai 200040China institutes of Biomedical Sciences Fudan University131 Dong An RoadShanghai 200032China

Background The efficacy of immune checkpoint inhibitors(ICIs),such as programmed cell death protein-1(PD-1)or its ligand 1(PD-L1)antibody,in hepatocellular carcinoma(HCC)is limited,and it is recommended that they be combined with other *** evaluated the combination of pegylated interferon-α(Peg-IFNα)with PD-1 blockade in HCC mouse *** We analyzed the effects of Peg-IFNαon tumor-infiltrating immune cells and PD-1 expression in the HCC immune microenvironment and examined the underlying mechanism of its unique effect on the PD-1 *** in vivo efficacy of anti-PD-1 and Peg-IFNαwas evaluated in both subcutaneous and orthotopic mouse models of *** The combination of Peg-IFNαwith PD-1 blockade dramatically enhanced T-cell infiltration,improved the efficacy of PD-1 antibody and prolonged mouse survival compared with PD-1 antibody ***,Peg-IFNαcould recruit cytotoxic CD8+T cells to infiltrate the HCC microenvironment by inducing tumor cells to secrete the chemokine ***,the HCC microenvironment quickly overcame the immune responses by upregulating PD-1 expression in CD8+T cells via the IFNα-IFNAR1-JAK1-STAT3 signaling *** combination of PD-1 blockade with Peg-IFNαcould restore the cytotoxic capacity of CD8+T cells and exerted a significant synergistic effect on *** These results indicate that in addition to initiating the antitumor immune response itself,Peg-IFNαcan also generate a microenvironment favoring PD-1 ***,the combination of Peg-IFNαand PD-1 blockade can be a promising strategy for HCC.

关键词： Hepatocellular carcinoma Tumor microenvironment PD-1 pegylated interferon-α T-cell exhaustion

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety

引用

World Journal of Hepatology 2014年第5期6卷 326-339页

作者： Igor Bakulin Victor Pasechnikov Anna Varlamicheva Irina Sannikova Central Scientific Research Institute of Gastroenterology of Moscow Clinical Scientific Center 111123 Moscow Russia Stavropol State Medical University 355020 Stavropol Russia

A new treatment paradigm for hepatitis C is that the treatment must include an existing direct-acting antiviral agent, namely, a protease inhibitor(PI) combined with pegylated interferon-a and ribavirin. The currently mar-keted PIs and PIs in clinical trials have different mecha-nisms of action. The development of new PIs aims for an improved safety profile and higher effectiveness. This article reviews NS3/4A protease inhibitors, focusing on major criteria such as their effectiveness and safety. Specific attention is paid to dosing regimens and adverse event profiles of PIs administered in clinical settings.

关键词： Protease inhibitor pegylated interferon-α Ribavirin Antiviral treatment Adverse event Response-guided therapy Hepatitis C virus

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：